Join UroGen Pharma for an investor webcast with members of the company’s leadership team, who will discuss UroGen’s long-term growth strategy for developing novel, locally administered therapies for urological and specialty cancers. The event will focus on the expansion of UroGen’s oncology pipeline through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. 

A live question and answer session will follow the formal presentation.